Physician profile
Niharika Marpu
NPI 1861827594
$6,743.06
in general payments reported to CMS, 2019-2025
32 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $397 · 2021: $700 · 2022: $2,019 · 2023: $1,346 · 2024: $733 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.64 |
| Education | $213.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,488.49 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $770.44 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $760.50 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $487.84 | 2020-2024 | Cuvitru, Eohilia |
| Amgen INC. | $468.46 | 2022-2025 | Tezspire |
| Genzyme Corporation | $369.85 | 2019-2025 | |
| Octapharma USA, INC. | $329.87 | 2019-2023 | Cutaquig |
| Kaleo, INC. | $248.42 | 2022-2024 | Auvi-Q |
| Optinose US, INC. | $193.98 | 2020-2025 | |
| Csl Behring | $183.51 | 2019-2023 | Hizentra, Haegarda |
| Abbvie INC. | $180.34 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $160.01 | 2019-2025 | |
| Pfizer INC. | $155.89 | 2019-2024 | |
| Genentech USA, INC. | $131.53 | 2019-2025 | Xolair |
| Shire North American Group INC | $112.47 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $108.38 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Ars Pharmaceuticals Operations, INC. | $83.75 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $74.99 | 2023 | |
| Aimmune Therapeutics, INC. | $73.15 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $61.34 | 2019-2021 | |
| Grifols USA, LLC | $51.64 | 2021-2022 | |
| Pharming Healthcare, INC. | $44.79 | 2021-2024 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.06 | 2022 | |
| Greer Laboratories, INC. | $32.25 | 2024 | Palforzia |
| Leo Pharma INC. | $25.65 | 2024 | Adbry |
| Blueprint Medicines Corporation | $23.35 | 2023 | Ayvakit |
| Mylan Specialty L.P. | $21.28 | 2021 | |
| Electromed, INC. | $15.80 | 2024 | Smartvest |
| Kedrion Biopharma, INC. | $13.91 | 2024 | Kedrab, Koate, Gammaked |
| Hospira, INC. | $13.11 | 2019 | |
| Hikma Pharmaceuticals USA | $12.84 | 2023 | Ryaltris |
| Biocryst US Sales Co., LLC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niharika Marpu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.